Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
UNAIDS plan to “Fast Track” end of AIDS means prioritizing men who have sex with men, people who inject drugs, sex workers, transgender people, women and girls
To reach 90/90/90 by 2020, those left invisible and unnamed will have to be recognized and supported, supporters of strategy say Fast Track, the strategy geared […]
BARCELONA, Spain – The opening press conference of the 45th Union World Conference on Lung Health highlighted a new report calling for international action against the latest co-epidemic, tuberculosis […]
The U.S. National Institute of Allergy and Infectious Diseases will begin human testing of a vaccine candidate to prevent Ebola virus disease at the National Institutes […]
At the end of last May, Dr. William Fischer was immersed in his work as a physician, researcher, and instructor at the University of North Carolina […]